

**South East London Area Prescribing Committee
Formulary recommendation**

Reference	068
Intervention:	Brimonidine 3mg/g gel (Mirvaso[®]) for the topical symptomatic treatment of facial erythema of rosacea (Brimonidine gel is applied to the skin of the face to treat redness due to rosacea)
Date of Decision	May 2017
Date of Issue:	June 2017
Recommendation:	Grey – not recommended for prescribing in South East London
Further Information	<ul style="list-style-type: none"> • Brimonidine topical gel (Mirvaso[®]) is not recommended for prescribing in South East London. • In 2 short-term randomised controlled trials (n=553; active treatment period of 4 weeks) brimonidine tartrate gel was statistically significantly more effective than vehicle gel in reducing erythema in people with a clinical diagnosis of rosacea and moderate to severe erythema. • However, 'success rates' (defined as a 2-grade reduction in the severity of erythema as assessed by both patients and clinicians) were just 25% to 30% with brimonidine gel compared with about 10% for vehicle gel at day 29. • The evidence provided only covers short term use. However, in the real world setting, the preparation is likely to be used long term as rosacea is a chronic condition. Data supporting long term safety and efficacy are lacking. • The Committee also considered use of brimonidine gel to be cosmetic in nature. In line with the South East London Treatment Access policy, cosmetic procedures are considered low priority by local commissioners and are only funded in exceptional circumstances.
Shared Care/Transfer of care document required:	N/A
Cost Impact for agreed patient group	N/A
Usage Monitoring & Impact Assessment	Trusts – monitor non-formulary requests and provide data to the APC upon request
	CCGs – monitor impact data and exception reports from GPs if inappropriate requests to prescribe are made to primary care.

Evidence reviewed	References (extracted from evidence evaluation) <ol style="list-style-type: none"> 1. NICE Evidence summary ESNM43: Facial erythema of rosacea: brimonidine tartrate gel. Published date: July 2014 2. Summary of product characteristics (SmPC) for Mirvaso® 3mg/g Gel Galderma (U.K) Ltd. Accessed via www.medicines.org.uk on 03/05/2017. 3. Fowler J, Jackson JM, Moore A et al. (2013) Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. <i>Journal of Drugs in Dermatology</i> 12: 650–6. Additionally: 4. South East London Treatment Access policy 2017, available here
--------------------------	--

NOTES:

- a) Area Prescribing Committee recommendations and minutes are available publicly on member CCG websites.
- b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.
- c) **Not to be used for commercial or marketing purposes. Strictly for use within the NHS.**